• Divya Menon
• Supriya Mahajan

Tuberculosis is a highly infectious disease and poses a threat to the wellbeing of people. Mycobacterium tuberculosis, the causative agent of the disease, develops resistance to antitubercular drugs and has the ability to lie dormant in the host, reactivating when the host is immunocompromised. Since it is seen that Mycobacterium tuberculosis can develop resistance to a drug, which targets a single protein or enzymatic pathway with ease, molecules which can have multiple targets need to be designed and materialized. Here, we report the docking results and interaction of twenty-six disubstituted 1, 3, 5-triazine derivatives as dihydrofolate reductase (DHFR) and enoyl acyl carrier protein reductase (InhA) inhibitors.

Mycobacterium tuberculosis, dual enzyme inhibitors, DHFR, InhA

"Molecular docking studies of disubstituted 1, 3, 5-triazine derivatives as dual enzyme inhibitors in Mycobacterium tuberculosis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.6, Issue 6, page no.202-210, June 2019, Available :http://www.jetir.org/papers/JETIR1908334.pdf

"Molecular docking studies of disubstituted 1, 3, 5-triazine derivatives as dual enzyme inhibitors in Mycobacterium tuberculosis", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.6, Issue 6, page no. pp202-210, June 2019, Available at : http://www.jetir.org/papers/JETIR1908334.pdf